Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.14
20.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai MicroPort MedBot Group Co Ltd
Cost of Revenue
Shanghai MicroPort MedBot Group Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
Cost of Revenue
-¥89.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Cost of Revenue
-¥486.1m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Cost of Revenue
-¥3.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-14%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Cost of Revenue
-¥13.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Cost of Revenue
-¥550.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Cost of Revenue
-¥5.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai MicroPort MedBot Group Co Ltd
Glance View
Shanghai MicroPort MedBot Group Co Ltd is a dynamic player in the medical innovation sector, strategically positioned at the crossroads of advanced technology and healthcare. Born out of a vision to revolutionize surgical practices, MedBot has dedicated itself to the development and commercialization of robotic-assisted systems. The company leverages cutting-edge research and development to create robotic platforms that aid surgeons in performing complex procedures with enhanced precision and control. Operating in a field where precision is paramount, MedBot's products are designed to minimize complications and reduce recovery times, catering to a global demand for improved surgical outcomes. MedBot generates its revenue by selling these sophisticated surgical robots to hospitals and healthcare institutions worldwide. Beyond the initial sale, the company benefits from offering ongoing service contracts, training, and support to ensure seamless integration and optimal performance of their products. Additionally, it capitalizes on the sale of consumables and replacement parts required for the long-term operation of their systems. Through its commitment to innovation and focus on addressing the complexities of surgical procedures, Shanghai MicroPort MedBot Group has carved out a distinctive niche, continually expanding its influence within the expanding scope of minimally invasive surgery.
See Also
What is Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue?
Cost of Revenue
-89.9m
CNY
Based on the financial report for Dec 31, 2023, Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue amounts to -89.9m CNY.
What is Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-498%
Over the last year, the Cost of Revenue growth was -498%.
You don't have any saved screeners yet
